Sorin Group, , a global medical device company and a leader in the treatment of cardiovascular diseases, announced today it has received U.S. Food and Drug Administration approval of its Investigational Device Exemption application and clinical trial protocol to begin evaluating its PERCEVAL S sutureless aortic tissue valve.
http://www.businesswire.com/news/topix/20130429005428/en
http://www.businesswire.com/news/topix/20130429005428/en
No comments:
Post a Comment